The 71 references in paper I. Guchev A., S. Sidorenko V., И. Гучев А., С. Сидоренко В. (2014) “Политика рациональной антибактериальной терапии обострения хронической обструктивной болезни легких: подход, основанный на минимизации риска параллельного ущерба // Strategy of rational antibacterial therapy of acute exacerbation of chronic obstructive pulmonary disease: an approach based on minimal hazard risk” / spz:neicon:pulmonology:y:2013:i:4:p:102-108

1
Lopez A.D., Shibuya K., Rao C. et al.Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397–412.
(check this in PDF content)
2
Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
(check this in PDF content)
3
World Bank / WHO Global Burden of Disease Study. Avail able from URL: http://www.who.int/mediacentre/factsheets/ fs310/en/index.html. Last access 2013-10-01.
(check this in PDF content)
4
European Respiratory Society. European Lung White Book: Huddersfield. Eur. Respir. Soc. J. Ltd; 2003.
(check this in PDF content)
5
Vestbo J., Hurd S.S., Agusti A.G. et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347–365.
(check this in PDF content)
6
Papaioannou A.I., Bartziokas K., Tsikrika S. et al. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur. Respir. J. 2013; 41: 815–823.
(check this in PDF content)
7
Atlantis E., Fahey P., Cochrane B. et al. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest 2013; 144: 766–777.
(check this in PDF content)
8
Motegi T., Jones R.C., Ishii T. et al. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 259–271.
(check this in PDF content)
9
Pauwels R.A.National and international guidelines for COPD: the need for evidence. Chest 2000; 117: 20S–22S.
(check this in PDF content)
10
Sethi S. Infection as a comorbidity of COPD. Eur. Respir. J. 2010; 35: 1209–1215
(check this in PDF content)
11
Patel I.S., Seemungal T.A., Wilks M. et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759–764.
(check this in PDF content)
12
Sethi S., Evans N., Grant B.J. et al.New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347: 465–471.
(check this in PDF content)
13
Sethi S., Wrona C., Eschberger K. et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 491–497.
(check this in PDF content)
14
Sethi S., Murphy T.F.Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355–2365.
(check this in PDF content)
15
Burge S., Wedzicha J.A.COPD exacerbations: definitions and classifications. Eur. Respir. J. Suppl. 2003; 41: 46s–53s.
(check this in PDF content)
16
Rodriguez3Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S–401S.
(check this in PDF content)
17
Soyseth V., Bhatnagar R., Holmedahl N.H. et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013; 99: 122–126.
(check this in PDF content)
18
Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest 2013; 143: 798–807.
(check this in PDF content)
19
Houghton A.M. Mechanistic links between COPD and lung cancer. Nature Rev. Cancer 2013; 13: 233–245.
(check this in PDF content)
20
McGarvey L.P., Magder S., Burkhart D. et al.Cause-specific mortality adjudication in the UPLIFT(R) COPD trial: findings and recommendations. Respir. Med. 2012; 106: 515–521.
(check this in PDF content)
21
Connors A.F. Jr, Dawson N.V., Thomas C. et al.Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to understand prognoses and preferences for outcomes and risks of treatments). Am. J. Respir. Crit. Care Med. 1996; 154: 959–967.
(check this in PDF content)
22
Boixeda R., Rabella N., Sauca G. et al.Microbiological study of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and the usefulness of analytical and clinical parameters in its identification (VIRAE study). Int. J. Chron. Obstruct. Pulm. Dis. 2012; 7: 327–335. Гучев И.А., Сидоренко С.В. Политика рациональной антибактериальной терапии обострения ХОБЛ Обзоры
(check this in PDF content)
23
Kim N., Leeper K.V. Jr.Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis. Semin. Respir. Crit. Care Med. 2000; 21: 73–78.
(check this in PDF content)
24
Reissig A., Mempel C., Schumacher U. et al. Microbiological diagnosis and antibiotic therapy in patients with community-acquired pneumonia and acute COPD exacerbation in daily clinical practice: comparison to current guidelines. Lung 2013; 191: 239–246.
(check this in PDF content)
25
Domenech A., Ardanuy C., Pallares R. et al.Some pneumococcal serotypes are more frequently associated with relapses of acute exacerbations in COPD patients. PLoS One 2013; 8: e59027.
(check this in PDF content)
26
Anzueto A., Niederman M.S., Tillotson G.S. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin. Ther. 1998; 20: 885–900.
(check this in PDF content)
27
Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548
(check this in PDF content)
28
Sayiner A., Okyay N., Unsal I. et al. Infective exacerbations of COPD. Chest 1999; 115: 1481.
(check this in PDF content)
29
Авдеев С.Н., Шанина А.Г., Чучалин А.Г.Бактериальная инфекция у больных ХОБЛ с острой дыхательной недостаточностью. Клин. микробиол. и антимикроб. химиотер. 2005; 7: 245–254.
(check this in PDF content)
30
Hvidsten D., Halvorsen D.S., Berdal B.P. et al.Chlamydophila pneumoniae diagnostics: importance of methodology in relation to timing of sampling. Clin. Microbiol. Infect. 2009; 15: 42–49.
(check this in PDF content)
31
Goh S.K., Johan A., Cheong T.H. et al. A prospective study of infections with atypical pneumonia organisms in acute exacerbations of chronic bronchitis. Ann. Acad. Med. Singapore 1999; 28: 476–480.
(check this in PDF content)
32
Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother. 1999; 43 (Suppl. A): 97–105.
(check this in PDF content)
33
Tang L.F., Wang D.F., Cao L.Q. et al. [Correlation between Chlamydia pneumoniae infection and chronic obstructive pulmonary disease]. Zhonghua Liu Xing Bing Xue Za Zhi 2012; 33: 1072–1074.
(check this in PDF content)
34
Dagan R., Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect. Dis. 2002; 2: 593–604.
(check this in PDF content)
35
Lieberthal A.S., Carroll A.E., Chonmaitree T. et al.The diagnosis and management of acute otitis media. Pediatrics 2013; 131: e964–999.
(check this in PDF content)
36
Woodhead M., Blasi F., Ewig S. et al.Guidelines for the management of adult lower respiratory tract infections – full version. Clin. Microbiol. Infect. 2011; 17 (Suppl. 6): E1–Е59.
(check this in PDF content)
37
Jacobs M.R., Felmingham D., Appelbaum P.C. et al.The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.
(check this in PDF content)
38
Maimon N., Nopmaneejumruslers C., Marras T.K.Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur. Respir. J. 2008; 31: 1068–1076.
(check this in PDF content)
39
Mulholland S., Gavranich J.B., Gillies M.B. et al.Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst. Rev. 2012; 9: CD004875.
(check this in PDF content)
40
Guchev I.A., Yu V.L., Sinopalnikov A. et al. Management of nonsevere pneumonia in military trainees with the urinary antigen test for Streptococcus pneumoniae: an innovative approach to targeted therapy. Clin. Infect. Dis. 2005; 40: 1608–1616.
(check this in PDF content)
41
Mohan A., Chandra S., Agarwal D. et al.Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology 2010; 15: 536–542.
(check this in PDF content)
42
Holm A., Pedersen S.S., Nexoe J. et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br. J. Gen. Pract. 2007; 57: 555–560.
(check this in PDF content)
43
Meer V., Neven A.K., van den Broek P.J. et al. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. Br. Med. J. 2005; 331: 26.
(check this in PDF content)
44
Engel M.F., Paling F.P., Hoepelman A.I. et al. Evaluating the evidence for the implementation of C-reactive protein measurement in adult patients with suspected lower respiratory tract infection in primary care: a systematic review. Fam. Pract. 2012; 29 (4): 383–393.
(check this in PDF content)
45
Graffelman A.W., Knuistingh Neven A., le Cessie S. et al. A diagnostic rule for the aetiology of lower respiratory tract infections as guidance for antimicrobial treatment. Br. J. Gen. Pract. 2004; 54: 20–24.
(check this in PDF content)
46
Stefan M.S., Rothberg M.B., Shieh M.S. et al.Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest 2013; 143: 82–90.
(check this in PDF content)
47
File T.M. Jr, Monte S.V., Schentag J.J. et al.A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. Int. J. Antimicrob. Agents 2009; 33: 58–64.
(check this in PDF content)
48
Mannino D.M., Davis K.J., Kiri V.A. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir. Med. 2009; 103 (2): 224–229.
(check this in PDF content)
49
Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
(check this in PDF content)
50
Stockley R.A., O'Brien C., Pye A. et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–1645.
(check this in PDF content)
51
Sapey E., Stockley R.A. COPD exacerbations. 2: aetiology. Thorax 2006; 61: 250–258.
(check this in PDF content)
52
O'Donnell D.E., Aaron S., Bourbeau J. et al.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2003. Can. Respir. J. 2003; 10 (Suppl. A): 11A–65A.
(check this in PDF content)
53
Ram F.S., Rodriguez3Roisin R., Granados3Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 2: CD004403.
(check this in PDF content)
54
Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniaeк антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового исследования ПеГАС). Клин. микробиол. и антимикроб. химиотер. 2010; 12: 329–341.
(check this in PDF content)
55
Schentag J.J., Klugman K.P., Yu V.L. et al. Streptococcus pneumoniaebacteraemia: pharmacodynamic correlations with outcome and macrolide resistance – a controlled study. Int. J. Antimicrob. Agents 2007; 30: 264–269.
(check this in PDF content)
56
Lisby J.G., Brasholt M., Teglbjoerg L.L.[Bacteremia and meningitis caused by Streptococcus pneumoniaeduring treatment with azithromycin]. Ugeskr. Laeg. 2002; 164: 2629.
(check this in PDF content)
57
Kelley M.A., Weber D.J., Gilligan P. et al.Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. 2000; 31: 1008–1011.
(check this in PDF content)
58
Jackson M.A., Burry V.F., Olson L.C. et al.Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr. Infect. Dis. J. 1996; 15: 1049–1051.
(check this in PDF content)
59
Kronman M.P., Hersh A.L., Feng R. et al.Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994–2007. Pediatrics 2011; 127: 411–418.
(check this in PDF content)
60
Chow A.W., Benninger M.S., Brook I. et al.IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clin. Infect. Dis. 2012; 54: e72–e112.
(check this in PDF content)
61
Lorenz J. Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis. Chemotherapy 1998; 44 (Suppl. 1): 15–18.
(check this in PDF content)
62
Falagas M.E., Avgeri S.G., Matthaiou D.K. et al.Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother. 2008; 62: 442–450.
(check this in PDF content)
63
Garcia3Cobos S., Arroyo M., Perez3Vazquez M. et al. Isolates of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae causing invasive infections in Spain remain susceptible to cefotaxime and imipenem. J. Antimicrob. Chemother. 2013 [Epub ahead of print].
(check this in PDF content)
64
Jansen W.T., Verel A., Beitsma M. et al.Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada. Curr. Med. Res. Opin. 2008; 24: 2853–2861.
(check this in PDF content)
65
Schneider C., Jick S.S., Bothner U. et al. COPD and the risk of depression. Chest 2010; 137: 341–347.
(check this in PDF content)
66
Minoretti P., Politi P., Martinelli V. et al. QT interval duration in apparently healthy men is associated with depression-related personality trait neuroticism. J. Psychosom. Res. 2006; 61: 19–23.
(check this in PDF content)
67
Kaye A.D., Volpi3Abadie J., Bensler J.M. et al. QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes. J. Anesth. 2013; 27: 575–587.
(check this in PDF content)
68
Food and Drug Administration (USA) Safety Information. Azithromycin (Zithromax or Zmax): Drug Safety Communication – Risk of Potentially Fatal Heart Rhythms. Available at URL: http://www.fda.gov/safety/medwatch/safe3 tyinformation/safetyalertsforhumanmedicalproducts/ucm3433 50.htm. [Posted 03/12/2013]. Last accessed 2013-10-01.
(check this in PDF content)
69
Jenkins C.R., Jones P.W., Calverley P.M. et al. Efficacy of salmeterol / fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10: 59.
(check this in PDF content)
70
Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
(check this in PDF content)
71
Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138. Информация об авторах Гучев Игорь Анатольевич – к. м. н., начальник терапевтического отде-
(check this in PDF content)